This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eckardt, J. R. Articles by Ross, G. Search for Related Content PubMed PubMed Citation Articles by Eckardt, J. R. Articles by Ross, G. Related Articles Related Editorial

Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer

John R. Eckardt, Joachim von Pawel, Zsolt Papai, Antoaneta Tomova, Valentina Tzekova, Theresa E. Crofts, Sarah Brannon, Paul Wissel, Graham Ross

From The Center for Cancer Care and Research, St Louis, MO; Zentralkrankenhaus Gauting, Gauting bei Muenchen, Germany; Koranyi National Institute of Pulmonology, Budapest, Hungary; Oncology Dispensary, Plovdiv, Bulgaria; University Hospital Tzaritza Joanna, Sofia, Bulgaria; GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Harlow, United Kingdom

Address reprint requests to John Eckardt, MD, The Center for Cancer Care and Research, 12855 N Outer Forty Dr, Suite 200, St Louis, MO 63141; jeckardt{at}tcccr.com

PURPOSE: This open-label, randomized, multicenter phase III study compared oral topotecan/intravenous cisplatin (TC) with intravenous (IV) etoposide/cisplatin (PE) in patients with untreated extensive-disease small-cell lung cancer (ED-SCLC).

PATIENTS AND METHODS: A total of 784 patients were randomly assigned to either oral topotecan 1.7 mg/m²/d x 5 with IV cisplatin 60 mg/m² on day 5 (n = 389) or IV etoposide 100 mg/m²/d x 3 with IV cisplatin 80 mg/m² on day 1 (n = 395) every 21 days.

RESULTS: Overall survival (primary end point) was similar between groups (P = .48; median: TC, 39.3 weeks v PE, 40.3 weeks). One-year survival was 31% (95% CI, 27% to 36%) in both groups and the difference of –0.03 (95% CI, –6.53 to 6.47) met the predefined criteria of 10% absolute difference for noninferiority of TC relative to PE. Response rates were similar between groups (TC, 63% v PE, 69%). Time to progression was slightly but statistically longer with PE (log-rank P = .02; median: TC, 24.1 weeks v PE, 25.1 weeks). The regimens were similarly tolerable. Grade 3/4 neutropenia occurred more frequently with PE (84% v 59%), whereas grade 3/4 anemia and thrombocytopenia occurred more frequently with TC (38% v 21% and 38% v 23%, respectively). Lung Cancer Symptom Scale scores were statistically better with PE, but the differences were small and of debatable clinical significance.

CONCLUSION: Oral topotecan with cisplatin provides similar efficacy and tolerability to the standard (etoposide with cisplatin) in untreated ED-SCLC and may provide greater patient convenience compared with intravenous etoposide and cisplatin.

Supported by GlaxoSmithKline, Middlesex, United Kingdom.

Presented at the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004, and at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Editorial

• Reponses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes?
  Michael C. Perry
  JCO 2006 24: 1980-1981 [Full Text]

This article has been cited by other articles:

				B. Freidlin, E. L. Korn, S. L. George, and R. Gray Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is Expected J. Clin. Oncol., November 1, 2007; 25(31): 5019 - 5023. [Abstract] [Full Text] [PDF]

				D. H. Lee, S.-W. Kim, K.-S. Bae, J.-S. Hong, C. Suh, Y.-K. Kang, and J.-S. Lee A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer Clin. Cancer Res., October 15, 2007; 13(20): 6182 - 6186. [Abstract] [Full Text] [PDF]

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				G. R. Simon and A. Turrisi Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 324S - 339S. [Abstract] [Full Text] [PDF]

				B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years? Oncologist, September 1, 2007; 12(9): 1096 - 1104. [Abstract] [Full Text] [PDF]

				C. Gridelli, C. Langer, P. Maione, A. Rossi, and S. E. Schild Lung Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1898 - 1907. [Abstract] [Full Text] [PDF]

				M. C. Perry Reponses to Topoisomerase-I Inhibitors in Extensive Small-Cell Lung Cancer: Chance or Chromosomes? J. Clin. Oncol., May 1, 2006; 24(13): 1980 - 1981. [Full Text] [PDF]